Treatment outcome comparisons of first‐line targeted therapy in patients with KRAS wild‐type metastatic colorectal cancer: A nationwide database study
Abstract Background The first‐line systemic therapy for metastatic colorectal cancer (mCRC) is a combination of one targeted therapy agent and a chemotherapy doublet. Whether bevacizumab or anti‐epidermal growth factor receptor (anti‐EGFR) monoclonal antibody (mAb) is the more effective addition to...
| Published in: | Cancer Medicine |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-07-01
|
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.6196 |